Medrhythms

What Medrhythms does

MedRhythms, Inc. is a Portland, Maine-based digital therapeutics company founded in 2013 that develops prescription neurotherapeutics to improve walking in patients with neurologic injury or disease. The company's proprietary EntrainRx platform combines shoe-clip gait sensors with a patented Audio Engine that delivers personalized rhythmic auditory stimulation (RAS) through music, continuously adapting the auditory stimulus in real time based on measured gait data to drive auditory-motor entrainment.

The company has two FDA Class II listed commercial products: InTandem, indicated for ambulatory adults with chronic stroke walking impairments (FDA-listed July 2023, prescription-available since October 2023), and MOVIVE, indicated to support gait rehabilitation and motor function in people with Parkinson's Disease (FDA Class II listing March 2025). Both products leverage the same underlying EntrainRx platform and are available by prescription only, with InTandem securing a dedicated CMS reimbursement code in August 2024 and a final Medicare payment determination in January 2025. The company's R&D pipeline targets additional indications including Multiple Sclerosis, acute stroke, functional neurological disorder, aging-in-place mobility, and cognition, supported by more than 50 published clinical studies on RAS efficacy.

MedRhythms generates revenue through prescription sales of InTandem and MOVIVE reimbursed under Medicare, commercial insurance, and VA coverage, distributed via a national agreement with Edwards Health Care Services (a GEMCORE Family Company) signed September 2025, supplemented by direct enterprise sales to hospitals and rehabilitation centers and an EVERSANA commercialization partnership. The company has raised over $50 million in cumulative funding from investors including Morningside Ventures, Advantage Capital, Werth Family Investment Associates, Global Brain Corporation, and Bose Ventures, and continues to raise growth capital through SEC-exempt offerings. Co-founder Brian Harris, one of approximately 350 Neurologic Music Therapist Fellows globally, leads the company alongside a leadership team that includes recent CEO transition to Lawrence Jasinski.

Name

Medrhythms

Legal name

MedRhythms, Inc.

Website

https://medrhythms.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

MedRhythms is a digital therapeutics company developing prescription neurotherapeutics that combine gait sensors, proprietary software, and personalized music to improve walking in patients with chronic stroke and Parkinson's disease, reimbursed through Medicare, commercial insurance, and VA channels.

Ownership category

akta.pro rank

Product category

Prescription Digital Therapeutics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

akta.pro secondary industries

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

Keywords

• Prescription digital therapeutics
• Neurologic music therapy
• Walking rehabilitation devices
• Rhythmic auditory stimulation
• Digital health therapeutics

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Prescription Digital Therapeutics: Revenue from prescription digital therapeutic products (InTandem and MOVIVE) sold to patients through healthcare providers and distribution partners, with reimbursement through Medicare, commercial insurance, and VA coverage
2. Healthcare Reimbursement: Products covered under CMS reimbursement codes, Medicare payment determination, and commercial insurance plans for stroke and Parkinson's patients
3. Securities Offering: Equity financing through SEC filings for ongoing operations and growth

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

MedRhythms develops and sells prescription digital therapeutics that combine shoe-mounted sensors capturing real-time gait data with proprietary clinical algorithms delivering personalized rhythmic auditory stimulation (RAS) through music. Its two commercialized products are InTandem, an FDA-listed Class II device for chronic stroke walking rehabilitation, and MOVIVE, an FDA Class II listed device for gait rehabilitation in Parkinson's disease. Products are available by prescription, reimbursed through Medicare, commercial insurance, and VA coverage, and distributed via healthcare providers and a national partnership with Edwards Health Care Services.

Product overview

MedRhythms is a prescription digital therapeutics company that has developed a proprietary technology platform called EntrainRx™. The platform combines sensors that capture real-time gait data with a personalized rhythmic stimulus delivered as music through proprietary clinical algorithms, based on rhythmic auditory stimulation (RAS). The company offers two commercialized products: InTandem® for chronic stroke walking impairment and MOVIVE® for Parkinson's Disease. Both products are available by prescription and leverage the same underlying platform technology to deliver personalized music-based neurotherapeutics that target neural circuitry to improve walking, mobility, and related functional outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• InTandem: Prescription digital therapeutic for ambulatory adults with stroke walking impairments. Indicated to improve walking and ambulation.
• MOVIVE
• EntrainRx

Products and services

• InTandem FDA Class II listed prescription digital therapeutic (MR-001) intended for ambulatory adults with chronic stroke walking impairments, designed for home or clinical use to improve walking and ambulation through personalized rhythmic auditory stimulation delivered as music via the EntrainRx platform.
• MOVIVE FDA Class II listed prescription music therapy device indicated to support gait rehabilitation and motor function for people with Parkinson's disease, delivering personalized rhythmic auditory stimulation through music on the EntrainRx platform.
• EntrainRx Platform Proprietary software platform that combines sensors capturing real-time gait data with personalized rhythmic stimulus delivered as music through proprietary clinical algorithms emulating rhythmic auditory stimulation (RAS) for auditory-motor entrainment; used to develop and iteratively refine neurotherapeutics for a range of neurologic conditions.

Quantifiable outcome

• InTandem users improved walking speed by 22% in 5 weeks, averaging 8.7 years post-stroke
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• Edwards Health Care Services (GEMCORE Family Company)coreChannel Partner/ Reseller/ Distributor · 16 September 2025National distribution agreement for InTandem and MOVIVE prescription music therapy devices. Expands patient access through Medicare, commercial insurance, and VA coverage, building on existing CMS reimbursement setup.
• LovellcoreChannel Partner/ Reseller/ Distributor · 8 November 2023Partnership to provide access to InTandem for Veterans and Military Personnel with walking impairment due to stroke.
• Universal Music GroupflagshipStrategic or Co-development Partner · 29 September 2021World's first prescription music platform collaboration providing patients access to the most diverse and culturally rich collection of music for therapeutic use. MedRhythms curates, augments, and individualizes clinical interventions using Universal Music Group's catalog.
• EVERSANAcoreStrategic or Co-development Partner · 19 May 2021Partnership to launch and commercialize chronic stroke software-based medical device. EVERSANA provides commercialization expertise for market entry.
• Massachusetts General HospitalcoreStrategic or Co-development Partner · 18 May 2021Collaboration on neuroimaging study in Multiple Sclerosis to advance understanding of how MedRhythms' technology affects neural pathways.
• Roux InstituteminorStrategic or Co-development Partner · 17 November 2020Partnership in the fields of neuroscience and artificial intelligence for research collaboration and talent development.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Kaia Health: Digital therapeutics company for MSK pain and chronic obstructive pulmonary disease using app-based exercise therapy. Comparable as a software-delivered rehabilitation therapy platform but focused on pain rather than gait/balance.
• NeuroPace: Developer of the RNS System, an FDA-approved implantable neurostimulation device for refractory epilepsy. Comparable as an FDA-regulated neuro-device company with prescription-driven commercial model, though targeting a different neurological condition.

Direct peers

• Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across neurology, psychiatry, and cardiometabolic indications. Comparable regulatory, reimbursement, and commercialization playbook to MedRhythms.
• Akili Interactive: Prescription digital therapeutics company with FDA-cleared EndeavorRx for ADHD and other cognitive therapeutics. Comparable as a prescription digital therapeutic company pursuing FDA clearance, reimbursement, and physician-prescribed distribution models.
• MindMaze: Digital neurotherapeutics company combining motion sensors, gamified therapy, and AI to drive recovery in stroke, traumatic brain injury, and Parkinson's. Closest analog to MedRhythms in combining sensor-based gait assessment with software-delivered neurological rehabilitation.
• Helius Medical Technologies: Developer of the Portable Neuromodulation Stimulator (PoNS) device, a prescription neurostimulation product for gait and balance rehabilitation in traumatic brain injury and multiple sclerosis. Highly comparable to MedRhythms as another prescription neurological-rehabilitation device targeting walking deficits with reimbursement-backed economics.

Broad incumbents

• Hinge Health: Largest digital musculoskeletal care platform, offering virtual PT, wearable sensors, and AI-guided exercise therapy for back, joint, and post-surgical rehabilitation. Comparable to MedRhythms in combining sensor data with software-delivered therapy, though operating at much broader scale across MSK conditions.
• Sword Health: Digital MSK and pelvic-health therapy company using wearable motion sensors and AI to deliver remote physical therapy. Shares MedRhythms' sensor-plus-software model for rehabilitation outcomes and pursues similar employer and payer channels.
• Omada Health: Public virtual-care platform delivering digital chronic-disease management including MSK, metabolic, and behavioral health. Comparable prescription/reimbursement model and payer-channel distribution approach, though at significantly larger scale and broader indication set.
• Penumbra: Public neurovascular device company with growing rehabilitation technology portfolio including Real iWave and other digital rehab offerings. Comparable as a broader neuro-focused device incumbent expanding into rehabilitation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MedRhythmsLLC
• Facebookfacebook.com/MedRhythmsLLC
• LinkedInlinkedin.com/company/5040839
• Instagraminstagram.com/medrhythms

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds14 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medrhythms